Mylan, Teva and Ranbaxy announced on Friday that they have each launched generic forms of Takeda’s blockbuster type 2 diabetes drug Actos in the US. The generic drugmakers are sharing 180-day exclusivity for the generic versions of the branded medication, which receives in sales of roughly $2.7 billion a year across America. Actos (pioglitazone) is
Ranbaxy Laboratories has launched generic versions of Pfizer’s Lipitor in four European countries, a couple of months prior to the patents running out on the cholesterol blockbuster. Ranbaxy is launching copies in Italy, the Netherlands and Sweden and noted that market sizes in these countries are $377 million, $164.4 million and $55 million, respectively. The
Generics major Teva Pharmaceutical Industries is set to enter the lucrative market created in the USA by the patent expiry on Pfizer’s Lipitor but not until Ranbaxy Laboratories’ 180-day exclusivity period runs out. The Israeli drugmaker noted that the US FDA (Food and Drug Administration) have granted tentative approval for their generic version of Lipitor,
